Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum: Evaluation of Clinical Practices in Five Maternity Hospitals in Île-de-France

February 21, 2025 updated by: Centre Hospitalier de Saint-Denis
This clinical trial aims to evaluate the adequacy of healthcare professionals' clinical practices regarding nausea and vomiting in pregnancy (NVP) and hyperemesis gravidarum (HG) with the recommendations of the National College of French Obstetricians and Gynecologists (CNGOF). The study involves 117 participants and follows an observational, cross-sectional, multicenter study design conducted in five maternity hospitals in Île-de-France.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

117

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Saint-Denis, France, 93200
        • Centre Hospitalier de Saint-Denis

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consisted of 117 healthcare professionals from five maternity hospitals in Île-de-France, of which 104 responses were usable. The participants included:

68 midwives (65.4%)

27 obstetrician-gynecologists (26%)

9 gynecology-obstetrics interns (8.6%)

The distribution across hospitals was as follows:

Center A: 45 respondents (21 midwives, 17 obstetrician-gynecologists, 7 interns)

Center B: 17 respondents (all midwives)

Center C: 15 respondents (12 midwives, 3 obstetrician-gynecologists)

Center D: 15 respondents (9 midwives, 4 obstetrician-gynecologists, 2 interns)

Center E: 12 respondents (9 midwives, 3 obstetrician-gynecologists)

Description

Inclusion Criteria:

  • Midwives, obstetrician-gynecologists, and gynecology-obstetrics interns working in the labor and delivery units, high-risk pregnancy units, and obstetric-gynecological emergency units of the five selected maternity hospitals.

Exclusion Criteria:

  • Midwives or doctors in training (student midwives or medical externs)
  • Midwives and obstetrician-gynecologists working in private practice

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Midwives
Midwives involved in the care of patients suffering from nausea and vomiting of pregnancy and hypermesis gravidarum
Obstetrician-Gynecologists
Obstetrician-Gynecologists involved in the care of patients suffering from nausea and vomiting of pregnancy and hypermesis gravidarum
Gynecology-Obstetrics Interns
Gynecology-Obstetrics involved in the care of patients suffering from nausea and vomiting of pregnancy and hypermesis gravidarum

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of healthcare professionals whose management of NVP and HG aligns with CNGOF recommendations.
Time Frame: data collection period: October 2023-March 2024
data collection period: October 2023-March 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier de Saint-Denis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2023

Primary Completion (Actual)

March 1, 2024

Study Completion (Actual)

March 15, 2024

Study Registration Dates

First Submitted

February 18, 2025

First Submitted That Met QC Criteria

February 18, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 21, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0051_MATERNITE_

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe